S. Alampour-rajabi, E. Bounkari, O. Rot, A. Muller-newen, G. Bachelerie et al., MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP-70 signaling, and lymphocyte chemotaxis, FASEB J, vol.29, pp.4497-4511, 2015.

E. Bargagli, C. Olivieri, N. Nikiforakis, M. Cintorino, B. Magi et al., Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis, Respir Physiol Neurobiol, vol.167, pp.261-267, 2009.

J. Bernhagen, R. Krohn, H. Lue, J. L. Gregory, A. Zernecke et al., MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment, Nat Med, vol.13, pp.587-596, 2007.

P. Bonniaud, A. Fabre, N. Frossard, C. Guignabert, M. Inman et al., Optimising experimental research in respiratory diseases: an ERS statement, Eur Respir J, vol.51, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01996906

J. Bordenave, R. Thuillet, L. Tu, C. Phan, A. Cumont et al., Neutralization of CXCL12 attenuates established pulmonary hypertension in rats, Cardiovasc Res, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02366304

L. Bossini-castillo, D. Campillo-davo, E. Lopez-isac, F. D. Carmona, C. P. Simeon et al., An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis, J Rheumatol, vol.44, pp.1453-1457, 2017.

A. Boucly, J. Weatherald, L. Savale, X. Jais, V. Cottin et al., Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension, Eur Respir J, vol.50, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01757586

V. J. Burton, A. M. Holmes, L. I. Ciuclan, A. Robinson, J. S. Roger et al., Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II, Blood, vol.118, pp.4750-4758, 2011.

J. A. Canter, M. L. Summar, H. B. Smith, G. D. Rice, L. D. Hall et al., Genetic variation in the mitochondrial enzyme carbamyl-phosphate synthetase I predisposes children to increased pulmonary artery pressure following surgical repair of congenital heart defects: a validated genetic association study, Mitochondrion, vol.7, pp.204-210, 2007.

C. M. Costello, B. Mccullagh, K. Howell, M. Sands, J. A. Belperio et al., A role for the CXCL12 receptor, CXCR7, in the pathogenesis of human pulmonary vascular disease, Eur Respir J, vol.39, pp.1415-1424, 2012.

V. Cottin, L. C. Price, and C. Valenzuela, The unmet medical need of pulmonary hypertension in idiopathic pulmonary fibrosis, Eur Respir J, vol.51, 2018.

Z. Dai, M. M. Zhu, Y. Peng, H. Jin, N. Machireddy et al., Endothelial and Smooth Muscle Cell Interaction via FoxM1 Signaling Mediates Vascular Remodeling and Pulmonary Hypertension, American journal of respiratory and critical care medicine, vol.198, pp.788-802, 2018.

M. Dewor, G. Steffens, R. Krohn, C. Weber, J. Baron et al., Macrophage migration inhibitory factor (MIF) promotes fibroblast migration in scratch-wounded monolayers in vitro, FEBS Lett, vol.581, pp.4734-4742, 2007.

H. M. Dubrock, J. M. Rodriguez-lopez, B. L. Levarge, M. P. Curry, P. A. Vanderlaan et al., Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension, Pulm Circ, vol.6, pp.498-507, 2016.

P. M. Engelfriet, M. G. Duffels, T. Moller, E. Boersma, J. G. Tijssen et al., Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease, Heart, vol.93, pp.682-687, 2007.

D. Farkas, D. Kraskauskas, J. I. Drake, A. A. Alhussaini, V. Kraskauskiene et al., CXCR4 inhibition ameliorates severe obliterative pulmonary hypertension and accumulation of C-kit(+) cells in rats, PLoS One, vol.9, p.89810, 2014.

N. Galie, M. Humbert, J. L. Vachiery, S. Gibbs, I. Lang et al., ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the, ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), vol.46, pp.903-975, 2015.

N. Gambaryan, F. Perros, D. Montani, S. Cohen-kaminsky, M. Mazmanian et al., Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension, Eur Respir J, vol.37, pp.1392-1399, 2011.

M. A. Gatzoulis, M. Beghetti, M. J. Landzberg, and N. Galie, Pulmonary arterial hypertension associated with congenital heart disease: recent advances and future directions, Int J Cardiol, vol.177, pp.340-347, 2014.

G. Grieb, B. S. Kim, D. Simons, J. Bernhagen, and N. Pallua, MIF and CD74 -suitability as clinical biomarkers, Mini Rev Med Chem, vol.14, pp.1125-1131, 2014.

C. Guignabert and P. Dorfmuller, Pathology and Pathobiology of Pulmonary Hypertension. Seminars in respiratory and critical care medicine, vol.38, pp.571-584, 2017.

C. Guignabert, L. Tu, B. Girerd, R. N. Huertas, A. Montani et al., New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication, Chest, vol.147, pp.529-537, 2015.

S. Gunther, J. Bordenave, T. Hua-huy, C. Nicco, A. Cumont et al., Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis, Int J Mol Sci, vol.19, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02612651

S. Gunther, P. Fagone, G. Jalce, A. Atanasov, C. Guignabert et al., Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets, Drug Discov Today, 2018.

S. Gunther, P. Fagone, G. Jalce, A. G. Atanasov, C. Guignabert et al., Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets, Drug discovery today, vol.24, pp.428-439, 2019.

J. M. Harper, J. E. Wilkinson, and R. A. Miller, Macrophage migration inhibitory factor-knockout mice are long lived and respond to caloric restriction, FASEB J, vol.24, pp.2436-2442, 2010.

M. M. Hoeper, C. Lam, J. L. Vachiery, J. Bauersachs, C. Gerges et al., Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research, European heart journal, vol.38, pp.2869-2873, 2017.

N. Honma, H. Koseki, T. Akasaka, T. Nakayama, M. Taniguchi et al., Deficiency of the macrophage migration inhibitory factor gene has no significant effect on endotoxaemia, Immunology, vol.100, pp.84-90, 2000.

A. Huertas, C. Guignabert, J. A. Barbera, P. Bartsch, J. Bhattacharya et al., Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy, The European respiratory journal, vol.51, 2018.

A. Huertas, F. Perros, L. Tu, S. Cohen-kaminsky, D. Montani et al., Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay, Circulation, vol.129, pp.1332-1340, 2014.

A. Huertas, L. Tu, and C. Guignabert, New targets for pulmonary arterial hypertension: going beyond the currently targeted three pathways, Curr Opin Pulm Med, vol.23, pp.377-385, 2017.

M. Humbert, C. Guignabert, S. Bonnet, P. Dorfmuller, J. R. Klinger et al., Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives, Eur Respir J, vol.53, 2019.

M. Humbert, G. Monti, F. Brenot, O. Sitbon, A. Portier et al., Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension, American journal of respiratory and critical care medicine, vol.151, pp.1628-1631, 1995.

T. Kasama, S. Isojima, M. Umemura, H. Tsukamoto, T. Tokunaga et al., Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis, Rheumatol Int, vol.34, pp.429-433, 2014.

T. M. Kolb, N. Rafaels, L. Gao, K. Barnes, R. Girgis et al., Serum Macrophage Migration Inhibitory Factor (MIF) Is Increased In Patients With Pulmonary Arterial Hypertension, American journal of respiratory and critical care medicine, vol.183, p.1990, 2011.

T. M. Kolb, J. Varney, P. M. Hassoun, and R. L. Damico, Macrophage Migration Inhibitory Factor (MIF)-Deficient Mice Are Protected From Right Ventricular Remodeling In A Model Of Chronic Hypoxia-Induced Pulmonary Hypertension, American journal of respiratory and critical care medicine, vol.183, p.4971, 2011.

C. S. Lam, V. L. Roger, R. J. Rodeheffer, B. A. Borlaug, F. T. Enders et al., Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study, Journal of the American College of Cardiology, vol.53, pp.1119-1126, 2009.

L. Hiress, M. Akagah, B. Bernadat, G. Tu, L. Thuillet et al., Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension, J Med Chem, vol.61, pp.2725-2736, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02580381

L. Hiress, M. Tu, L. , R. N. Phan, C. Thuillet et al., Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex, American journal of respiratory and critical care medicine, vol.192, pp.983-997, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02579320

M. Li, S. R. Riddle, M. G. Frid, K. C. El-kasmi, T. A. Mckinsey et al., Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension, J Immunol, vol.187, pp.2711-2722, 2011.

P. Luedike, G. Alatzides, M. Papathanasiou, M. Heisler, J. Pohl et al., Circulating macrophage migration inhibitory factor (MIF) in patients with heart failure, Cytokine, vol.110, pp.104-109, 2018.

P. Luedike, G. Alatzides, M. Papathanasiou, M. Heisler, J. Pohl et al., Predictive potential of macrophage migration inhibitory factor (MIF) in patients with heart failure with preserved ejection fraction (HFpEF), Eur J Med Res, vol.23, p.22, 2018.

N. Y. Maeda, V. D. Aiello, P. C. Santos, A. M. Thomaz, L. J. Kajita et al., Relation of Macrophage Migration Inhibitory Factor to Pulmonary Hemodynamics and Vascular Structure and Carbamyl-Phosphate Synthetase I Genetic Variations in Pediatric Patients with Congenital Cardiac Shunts, Mediators Inflamm, p.7305028, 2019.

J. D. Marshall, M. Sauler, A. Tonelli, Y. Rao, R. Bucala et al., Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension, Pulm Circ, vol.7, pp.730-733, 2017.

D. Montani, F. Perros, N. Gambaryan, B. Girerd, P. Dorfmuller et al., C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension, Am J Respir Crit Care Med, vol.184, pp.116-123, 2011.

N. W. Morrell, M. A. Aldred, W. K. Chung, C. G. Elliott, W. C. Nichols et al., Genetics and genomics of pulmonary arterial hypertension, The European respiratory journal, vol.53, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02137830

S. Perveen, K. Ayasolla, N. Zagloul, H. Patel, K. Ochani et al., MIF inhibition enhances pulmonary angiogenesis and lung development in congenital diaphragmatic hernia, Pediatric research, vol.85, pp.711-718, 2019.

M. Rabinovitch, C. Guignabert, M. Humbert, and N. Mr, Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension, Circ Res, vol.115, pp.165-175, 2014.

D. Rajasekaran, S. Groning, C. Schmitz, S. Zierow, N. Drucker et al., Macrophage Migration Inhibitory Factor-CXCR4 Receptor Interactions: EVIDENCE FOR PARTIAL ALLOSTERIC AGONISM IN COMPARISON WITH CXCL12 CHEMOKINE, J Biol Chem, vol.291, pp.15881-15895, 2016.

T. Roger, A. Schneider, M. Weier, F. C. Sweep, L. Roy et al., High expression levels of macrophage migration inhibitory factor sustain the innate immune responses of neonates, Proc Natl Acad Sci U S A, vol.113, pp.997-1005, 2016.

K. E. Russell, K. F. Chung, C. J. Clarke, A. L. Durham, P. Mallia et al., The MIF Antagonist ISO-1 Attenuates Corticosteroid-Insensitive Inflammation and Airways Hyperresponsiveness in an Ozone-Induced Model of COPD, PLoS One, vol.11, p.146102, 2016.

E. Sartina, C. Suguihara, S. Ramchandran, P. Nwajei, M. Rodriguez et al., Antagonism of CXCR7 attenuates chronic hypoxia-induced pulmonary hypertension, Pediatr Res, vol.71, pp.682-688, 2012.

G. Simonneau, D. Montani, D. S. Celermajer, C. P. Denton, M. A. Gatzoulis et al., Haemodynamic definitions and updated clinical classification of pulmonary hypertension, Eur Respir J, vol.53, 2019.

E. Soon, A. M. Holmes, C. M. Treacy, N. J. Doughty, L. Southgate et al., Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension, Circulation, vol.122, pp.920-927, 2010.

K. Stefanantoni, I. Sciarra, M. Vasile, R. Badagliacca, R. Poscia et al., Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor beta in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension, Reumatismo, vol.66, pp.270-276, 2015.

M. L. Summar, L. D. Hall, A. M. Eeds, H. B. Hutcheson, A. N. Kuo et al., Characterization of genomic structure and polymorphisms in the human carbamyl phosphate synthetase I gene, Gene, vol.311, pp.51-57, 2003.

A. J. Sweatt, H. K. Hedlin, V. Balasubramanian, A. Hsi, L. K. Blum et al., Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension, Circulation research, vol.124, pp.904-919, 2019.

Y. Tamura, C. Phan, L. Tu, L. Hiress, M. Thuillet et al., Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension, The Journal of clinical investigation, vol.128, pp.1956-1970, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02580448

P. V. Tilstam, D. Qi, L. Leng, L. Young, and R. Bucala, MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics, Expert Opin Ther Targets, vol.21, pp.671-683, 2017.

A. C. Van-riel, M. J. Schuuring, I. D. Van-hessen, A. H. Zwinderman, L. Cozijnsen et al., Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification, Int J Cardiol, vol.174, pp.299-305, 2014.

N. F. Voelkel, J. Gomez-arroyo, A. Abbate, H. J. Bogaard, and N. Mr, Pathobiology of pulmonary arterial hypertension and right ventricular failure, The European respiratory journal, vol.40, pp.1555-1565, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02612634

D. A. White, L. Fang, W. Chan, E. F. Morand, H. Kiriazis et al., Pro-inflammatory action of MIF in acute myocardial infarction via activation of peripheral blood mononuclear cells, PLoS One, vol.8, p.76206, 2013.

B. Zhang, Y. Luo, M. L. Liu, J. Wang, D. Q. Xu et al., Macrophage migration inhibitory factor contributes to hypoxic pulmonary vasoconstriction in rats, Microvasc Res, vol.83, pp.205-212, 2012.

B. Zhang, M. Shen, M. Xu, L. L. Liu, Y. Luo et al., Role of macrophage migration inhibitory factor in the proliferation of smooth muscle cell in pulmonary hypertension, Mediators Inflamm, p.840737, 2012.

T. Zhang, N. Kawaguchi, E. Hayama, Y. Furutani, and T. Nakanishi, High expression of CXCR4 and stem cell markers in a monocrotaline and chronic hypoxia-induced rat model of pulmonary arterial hypertension, Exp Ther Med, vol.15, pp.4615-4622, 2018.

Y. Zhang, A. Talwar, D. Tsang, A. Bruchfeld, A. Sadoughi et al., Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension, Mol Med, vol.18, pp.215-223, 2012.

L. Zorzanelli, N. Y. Maeda, M. M. Clave, V. D. Aiello, M. Rabinovitch et al., Serum Cytokines in Young Pediatric Patients with Congenital Cardiac Shunts and Altered Pulmonary Hemodynamics, Mediators Inflamm, p.7672048, 2016.